Skip to content
OpenCapital
Get started

Amgen AMGN EVENITY — Total revenues

Other product segments

Repatha
$3.02B—
Other products
$1.53B+3.6%
Prolia
$727M-33.8%
TEPEZZA
$490M+28.6%
Otezla
$431M-1.4%
BLINCYTO
$415M+12.2%
Nplate
$412M+31.6%
XGEVA
$411M-27.4%
TEZSPIRE
$343M+20.4%
KYPROLIS
$330M+1.9%
ENBREL
$320M-37.3%
Aranesp
$311M-8.5%
Vectibix
$287M+7.5%
UPLIZNA
$262M+188%
IMDELLTRA/IMDYLLTRA
$258M+219%
KRYSTEXXA
$255M+8.1%

Similar metrics at other companies

Evolus logo
EOLSEvolysse — Total net revenues
$6.73M—
Regeneron Pharmaceuticals logo
REGNEYLEA — Revenue
$412.2M-45.4%
Regeneron Pharmaceuticals logo
REGNEvkeeza — Revenue
$53.3M+29.4%
IAR
IARTENT Solutions — Total Revenues
$41.2M-1.6%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Supernus Pharmaceuticals logo
SUPNOxtellar XR — Total revenues
$7.42M-27.2%

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$212.16B+30.0%
Enterprise value$268.92B+22.9%
P/E27.2×+2.5×
P/S5.7×+1.0×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's evenity — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's EVENITY — total revenues?
Amgen (AMGN) reported EVENITY — total revenues of $562M in Q1 2026.
How has Amgen's EVENITY — total revenues changed year-over-year?
Amgen's EVENITY — total revenues increased by 27.1% year-over-year, from $442M to $562M.
What is the long-term trend for Amgen's EVENITY — total revenues?
Over 4 years (2021 to 2025), Amgen's EVENITY — total revenues has grown at a 41.1% compound annual growth rate (CAGR), from $530M to $2.1B.
What does EVENITY — total revenues mean?
This metric represents the total gross sales generated from the commercialization of a specific bone-building therapeutic product. It reflects the market adoption, pricing power, and clinical demand for this treatment within the osteoporosis therapeutic category. Tracking this revenue stream provides insight into the product's lifecycle stage and its contribution to the company's overall biotechnology portfolio growth.